

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Suzuki, S.

Serial No. 09/880,573

Filed: June 13, 2001

Title: Protocadherin Materials and Methods


Group Art Unit: 1647

Examiner: David Romeo

## Certificate of First Class Mailing

I hereby certify that this paper is  
being filed by First Class Mail in an  
envelope, postage prepaid, addressed  
to the Commissioner for Patents,  
P.O. Box 1450, Alexandria, VA  
22313-1450.

September 24, 2003

  
Katherine L. Neville, Ph.D.RESPONSE TO RESTRICTION REQUIREMENT

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
OCT 02 2003  
TECH CENTER 1600/2900

Dear Sir:

This paper is filed in response to an outstanding Office Action, mailed July 24, 2003 in the above-mentioned application, in which the claims of the application were restricted into fifteen different groups of inventions

The claims were restricted as follows: Group I, claims 1, 4-7, 8, 11-14, drawn to protocadherin pc3 polynucleotides; Group II, claims 2, 4-7, 8, 11-14, drawn to protocadherin pc4 polynucleotides; Group III, claims 3, 4-7, 8, 11-14, drawn to protocadherin pc5 polynucleotides; Group IV, claim 15, drawn to pc3 polypeptides; Group V, claim 16, drawn to pc4 polypeptide; Group VI, claim 17, drawn to pc5 polypeptide; Group VII, claims 18, 21, 22, drawn to pc3-specific antibody; Group VIII, claims 19, 21, 22, drawn to pc4-specific antibody; Group IX, claims 20, 21, 22, drawn to pc5-specific antibody; Group X, claim 23, drawn to a method of contacting a pc3 polypeptide with a pc3 antibody; Group XI, claim 24, drawn to a method of contacting a pc3 polypeptide with a pc3 peptide ligand; Group XII, claim 25, drawn to a method of contacting a pc4 polypeptide with a pc4 antibody; Group XIII, claim 26, drawn to a method of contacting a pc4 polypeptide with a pc4 peptide ligand; Group XIV, claim 27, drawn to a method of contacting pc5 polypeptide with a pc5 antibody,

and Group XV, claim 28, drawn to a method of contacting pc5 polypeptide with a pc5 peptide ligand.

In response to the restriction, Applicants elect Group VII (claims 18, 21 and 22, drawn to protocadherin pc3 specific antibodies) without traverse.


It is submitted that the application is now in condition for allowance.  
Applicants respectfully request an early and favorable notification thereof.

Respectfully submitted,

**MARSHALL, GERSTEIN, & BORUN**  
6300 Sears Tower  
233 S. Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300  
Attorneys for Applicant

September 24, 2003

By

  
Katherine L. Neville, Ph.D.  
Registration No. 53,379